# US 10,478,419 B2 · Use of daphnoretin in prevention of tissue or organ transplant rejection or graft-versus-host-disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,419 B2
- Document ID: US10478419B2
- Status: Granted
- Kind: B2
- Application number: 16/038,198
- Filed: 2018-07-18
- Published: 2019-01-24
- Granted: 2019-11-19
- Earliest claimed: 2017-07-21
- Assignees: Mackay Memorial Hospital
- Applicants: MacKay Memorial Hospital
- Inventors: Yu-Jen Chen
- Web page: https://patentgrep.com/patent/US10478419B2

## CPC

- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of using daphnoretin to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host disease (GVHD). According to embodiments of the present disclosure, daphnoretin is administered to the recipient subject or to the donor organ prior to the transplantation to reduce immune response in the recipient subject against the transplanted organ, or to lower the risk of developing GVHD in the recipient subject.

## Claims

### Claim 1

A method for treating a tissue or organ transplant rejection or graft-versus-host disease (GVHD) in a subject in need thereof comprising administering to the subject an effective amount of daphnoretin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the daphnoretin is administered in an amount of 0.1-100 mg/Kg.

### Claim 3 (depends on 2)

The method of claim 2, wherein the daphnoretin is administered in the amount of 1-50 mg/Kg.

### Claim 4 (depends on 3)

The method of claim 3, wherein the daphnoretin is administered to the subject prior to the tissue or organ transplant.

### Claim 5 (depends on 1)

The method of claim 1, wherein the tissue is skin, stem cells, or bone marrow.

### Claim 6 (depends on 1)

The method of claim 1, wherein the organ is kidney, heart, liver, lung, or pancreas.

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering the daphnoretin to the donor tissue or organ prior to transplantation into the subject.

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering to the subject an immunosuppressive agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the immunosuppressive agent is selected from the group consisting of cyclosporine, dexamethasone, prednisone, azathioprine, fluorouracil, mercaptopurine, everolimus, sirolimus, tacrolimus, methotrexate, anthracycline, bleomycin, dactinomycin, mithramycin, mitomycin, rapamycin, and mycophenolate mofetil.

### Claim 10 (depends on 9)

The method of claim 9, wherein the immunosuppressive agent is rapamycin.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject is a human.